http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7655629-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1fbb22d7954557801160a9fd579bae9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M36-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate | 2003-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18795c72c9063e7a597beb9df53a00b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_318cd629c4d790688f44d24e26f265ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_270cd8af15854c762a4ddf762322b8ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afb41862096d9abd5f5ac93ecd831b86 |
| publicationDate | 2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7655629-B2 |
| titleOfInvention | Peptides and their use for the treatment of HIV infections |
| abstract | The invention relates to peptides with biological activity against infection having the amino acid sequence Z 1 -LE-X 1 -IP-X 2 -X 3 -X 4 -P-X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -K-X 11 -X 12 -X 13 -X 14 -X 15 -Z 2 , wherein X 1 is a lysine, alanine, or aspartic acid; X 2 is a cysteine, methionine or isoleucine; X 3 is a serine, cysteine, lysine or glycine; X 4 is an isoleucine, alanine, phenylalanine or cysteine; X 5 is a proline, D-proline or a substituted L- or D-proline; X 6 is a cysteine or glutamic acid; X 7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X 8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X 9 is an amino acid with an aromatic side chain; X 10 is a glycine, alanine or asparagine; X 11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X 12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X 13 is an amino acid with a hydrophobic or an aromatic side chain; X 14 is an amino acid with a hydrophobic or an aromatic side chain; X 15 is a phenylalanine or deletion; Z 1 is NH 2 or a sequence of 1 to 10 amino acid residues; Z 2 is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the provisio that (a) if X 12 is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X 13 , X 14 and X 15 are phenylalanine, valine and phenylalanine respectively; and/or (b) if X 12 is phenylalanine, than X 13 , X 14 and X 15 are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide. |
| priorityDate | 2002-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 417.